1. Rheinwald, J.G et al, “Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells” Cell. 6(3): 331-343. (1975)
2. Cima, L.G et al, “Tissue engineering by cell transplantation using degradable polymer substrates” Journal of Biomechanical Engineering. 113(2): 143-151. (1991)
3. Vacanti, C.A et al, “Synthetic polymers seeded with chondrocytes provide a template for new cartilage formation” Plast Reconstr Surg. 88(5): 753-759. (1991)
4. Langer, R. and J.P. Vacanti, “Tissue engineering” Science. 260(5110):920-926. (1993)
5. Fujimori, Y et al, “Skin regeneration for children with burn scar contracture using autologous cultured dermal substitutes and superthin auto-skin grafts - Preliminary clinical study” Ann Plas Surg. 57: 408-14. (2006)
6. Nishida, K et al, “Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium” The New England Journal of Medicine. 351: 1187-96. (2004)
7. O'Connor, N et al, “GRAFTING OF BURNS WITH CULTURED EPITHELIUM PREPARED FROM AUTOLOGOUS EPIDERMAL CELLS” The Lancet. 317(8211): 75-78. (1981)
8. Gallico, G.G, 3rd et al, “Permanent coverage of large burn wounds with autologous cultured human epithelium” The New England Journal of Medicine. 311(7): 448-451. (1984)
9. Pellegrini, G et al, “Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium” Lancet. 349(9057): 990-993. (1997)
10. Ochi, M et al, “Transplantation of cartilage-like tissue made by tissue engineering in the treatment of cartilage defects of the knee” J Bone Joint Surg Br. 84(4): 571-578. (2002)
11. Ma, P.X “Biomimetic materials for tissue engineering”. Adv Drug Deliv Rev. 60(2): 184-198. (2008)
12. 赤松延久 ” 日本における肝移植の現状について”. http://www.u-tokyo-hbp-transplant-surgery.jp/dl/report_01.pdf
13. Chamuleau RA, “(Bio)artificial liver support: ready for the patient?” Ned Tijdschr Tandheelkd. 123(5):243-7. (2016)
14. Mizumoto H et al, “A new culture technique for hepatocyte organoid formation and long-term maintenance of liver-specific functions.” Tissue Eng Part C Methods.14:167-75. (2008)
15. Yamamoto, H et al, “Enhanced liver functions in mouse hepatoma cells by induced overexpression of liver-enriched transcription factors.” Biochem. Eng. J. 60:67–73.(2012)
16. Ananthanarayanan A et al, “Purpose-driven biomaterials research in liver-tissue engineering.” Trends Biotechnol. 29: 110–118. (2011)
17. 酒井清孝, “人工臓器(2)代謝系人工臓器” (株)コロナ社 (2003)
18. 水野美淳, 田代仁正, 大河原久子, “肝臓と膵臓のはなし” (株)培風館 (1990)
19. Novikoff, A.B, “Cell heterogeneity within the hepatic lobule of the rat (staining reactions)” J Histochem Cytochem, 7(4): 240-244. (1959)
20. 持田智, “急性肝不全 ―概念，診断基準とわが国における実態―” 日消誌 112：813―821. (2015)
21. 江口豊, “劇症肝不全と人工肝臓” 人工臓器 37 巻 1 号 (2008)
22. 中村智之, 西田修, “人工肝臓” 人工臓器 43 巻 3 号 (2014)
23. 川村明夫, “肝昏睡も血液浄化で覚醒” Clin. Eng 3: 170-177. (1992)
24. Yoshiba, M et al, “Favorable Effect of new artificial liver support on survival of Patients with fulminant hepatic failure” Artif. Organs. 20 11: 1169-1172. (1996)
25. Rakhi Maiwall, Richard Moreau, “Plasma exchange for acute on chronic liver failure: is there a light at the end of the tunnel? ” Hepatol Int 10: 387–389. (2016)
26. 新田正和, “劇症肝炎に対する SPE+HFCHDF” 日アフェレシス会誌 22:198-205.(2003)
27. 西田修, “劇症肝不全に対する血液浄化法の知識と実践” 救急医学 32: 1699-706.(2008)
28. Abe T et al, “Study of plasma exchange for liver failure: beneficial and harmful effect.” The Apher Dial 8: 180-4. (2004)
29. Hassanein TI et al, “Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.” Hepatology 46: 1853-62. (2007)
30. Banares R et al, “Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure.” The RELIFE trial. Hepatology 57: 1153-62. (2013)
31. Laleman W et al, “Effect of the molecular adsorbent recirculating system and Prometheus device on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.” Crit Care 10: R108. (2006)
32. Kribben A et al, “Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.” Gastroenterology 142: 782-9. (2012)
33. 江口豊, “重症肝障害における Plasma Dia-filtration (PDF) –Plasma Filtration with Dialysis-療法” 日アフェレシス会誌 26: 310-4. (2007)
34. 小林直哉, “バイオ人工肝臓” 人工臓器 38 巻 3 号 (2009)
35. Demetriou, A et al, “Early clinical experience with a hybrid bioartificial liver.” Scandinavian Journal of Gastroenterology 30 sup208: 111-117. (1995)
36. Rozga, J et al, “Development of a hybrid bioartificial liver.” Ann Surg 217: 502–509. (1993)
37. Watanabe, F. D et al, “Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.” Ann. Surg. 225: 484-491. (1997)
38. Neuzil, Dan F et al, “Use of a novel bioartificial liver in a patient with acute liver insufficiency.” Surgery 113.3: 340-343. (1993)
39. Arkadopoulos, N et al,”‘Liver assist systems: state of the art.” The International journal of artificial organs 21.12: 781-787. (1998)
40. Samuel, Didier et al, “Neurological improvement during bioartificial liver sessions in patients with acute Liver failure awaiting transplantation1.” Transplantation 73.2: 257-264. (2002)
41. Bain, V. G., Montero, J. L. & de La Mata, M, “Bioartificial liver support.” Can J Gastroenterol 15: 313-318. (2001)
42. Demetriou, Achilles A et al, “Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.” Annals of surgery 239.5: 660-670. (2004)
43. Donini A, Baccarani U, Risalti A et al, “Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device.” Am J Gastroenterol, Apr 95 (4): 1102-4. (2000)
44. George V. Mazariegos, John F. Patzer II, Roberto C. Lopez et al, “First Clinical Use of a Novel Bioarti®cial Liver Support System (BLSS)” American Journal of Transplantation 2: 260-266. (2002)
45. Xue YL, Zhao SF, Luo Y et al, “TECA hybrid artificial liver support system in treatment of acute liver failure.” World J Gastroenterol. Dec 7(6): 826-9. (2001)
46. Yi-Tao Ding, Yu-Dong Qiu, Zhong Chen et al, “The development of a new bioartificial liver and its application in 12 acute liver failure patients” World J Gastroenterol 9(4): 829-832. (2003)
47. Sussman NL1, Gislason GT, Conlin CA, Kelly JH ”The Hepatix extracorporeal liver assist device: initial clinical experience.” Artif Organs. May 18(5): 390-6. (1994)
48. Antony Ellis AJ, Hughes RD, Wendon JA “Pilot-Controlled Trial of the Extracorporeal Liver Assist Devicein Acute Liver Failure” Hepatology. Dec 24(6): 1446-51. (1996)
49. VITAL THERAPIES ホームページより
50. Sauer IM, Gerlach JC, “Modular extracorporeal liver support.” Artif Organs. Aug 26(8): 703-6. (2002)
51. Flendrig, L. M. la Soe JW, Jörning GG et al, “In Vitro Evaluation of a Novel Bioreacotr Based on an Integral Oxygenator and a Spirally Wound Nonwoven Polyester Matrix for hepatocyte culture as small aggregates” J Hepatol. Jun 26(6): 1379-92. (1997)
52. Flendrig, L. M, Maas MA, Daalhuisen J et al, ‘Does the extend of the culture time of primary hepatocytes in a bioreactor affect the treatment efficacy of a bioartificial liver?.’ The International journal of artificial organs 21.9: 542-547. (1998)
53. Sosef MN. Van De Kerkhove MP, Abrahamse SL et al, “Blood coagulation in anhepatic pigs: Effects of treatment with the AMC-bioartificial liver.” J. Thromb. Haemost 1: 511–515. (2003)
54. Van De Kerkhove, M. P et al, “Phase I clinical trial with the AMC-bioartificial liver.” Int. J. Artif. Organs 25: 950–959. (2002)
55. Poyck, P.P., Hoekstra, R., van Wijk et al: “Functional and Morphological Comparison of Three Primary Liver Cell Types Cultured in the AMC Bioartificial Liver” LIVER TRANSPLANTATION 13: 589-598. (2007)
56. Miranda JP, Leite SB, Muller-Vieir U et al, “Towards an extended functional hepatocyte in vitro culture.” Tissue Eng. Part C vol. 15: 157–167. (2009)
57. Harrison S, Boquest A, Grupen C et al, “An efficient method for producing alpha(1,3)-galactosyltransferase gene knockout pigs.” Cloning Stem Cells. 6(4): 327-31. (2004)
58. Frühauf, Jan-Henning, Mertsching Heike et al, “Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells” Liver International. Volume 29, Number 10: 1553-1561(9). (2009)
59. Patience C, Takeuchi Y, Weiss RA et al, “Infection of human cells by an endogenous retrovirus of pigs.” Nat Med. Mar 3(3): 282-6. (1997)
60. Demetra Mavri-Damelin, Leonard H. Damelin, Simon Eaton et al: “Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia” Biotechnol. Bioeng, vol. 99: 644–651. (2008)
61. Mavri-Damelin D, Damelin LH, Eaton S et al, “Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia.” Biotechnol Bioeng. Feb 15;99(3): 644-51. (2008)
62. Kobayashi N, Fujiwara T, Westerman KA et al, “Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes.” Science. Feb 18;287(5456): 1258-62. (2000)
63. Totsugawa T, Yong C, Rivas-Carrillo JD, “Survival of liver failure pigs by transplantation of reversibly immortalized human hepatocytes with Tamoxifen- mediated self-recombination.” J Hepatol. Jul 47(1): 74-82. (2007)
64. Li J, Li LJ, Cao HC et al, “Establishment of highly differentiated immortalized human hepatocyte line with simian virus 40 large tumor antigen for liver based cell therapy.” ASAIO J. May-Jun 51(3): 262-8. (2005)
65. Schippers IJ, Moshage H, Roelofsen H et al: “Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation.” Cell Biol Toxicol. Jul 13(4-5): 375-86. (1997)
66. Werner A, Duvar S, Müthing J et al, “Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system.” Ann N Y Acad Sci. Jun 18 875: 364-368. (1999)
67. Kobayashi N, Okitsu T, Tanaka N et al, “Cell choice for bioartificial livers.” Keio J Med. Sep 52(3); 151-157. (2003)
68. Stock P, Staege MS, Muller LP et al, “Hepatocytes derived from adult stem cells.” Transplant Proc. 40: 620–623. (2008)
69. Saulnier N, Lattanzi W, Puglisi MA et al, “Mesenchymal stromal cells multipotency and plasticity: induction toward the hepatic lineage.” ur Rev Med Pharmacol Sci, 13(Suppl. 1): 71–78. (2009)
70. Sgodda M, Aurich H, Kleist S et al, “Hepatocyte differentiation of mesenchymal stem cells from rat peritoneal adipose tissue in vitro and in vivo.” Exp Cell Res 313: 2875–86. (2007)
71. Sato Y, Araki H, Kato J et al, “Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion.” Blood 106: 756–63. (2005)
72. Baertschiger RM, Serre-Beinier V, Morel P et al, “Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver.” PLoS ONE 4: e6657. (2009)
73. di Bonzo LV, Ferrero I, Cravanzola C et al, “Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential.” Gut 57: 223–31. (2008)
74. Oh SK, Chen AK, Mok Y et al, “Long-term microcarrier suspension cultures of human embryonic stem cells.” Stem Cell Res 2: 219–30. (2009)
75. Hay DC, Fletcher J, Payne C et al, “Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling.” Proc Natl Acad Sci U S A 105(34): 12301–6. (2008)
76. Lu H, Wang Z, Zheng Q et al, “Efficient differentiation of newly derived human embryonic stem cells from discarded blastocysts into hepatocyte-like cells.” J Dig Dis 11: 376–82. (2010)
77. Touboul T, Hannan NR, Corbineau S et al, “Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development.” Hepatology 51: 1754–65. (2010)
78. Hay DC, Zhao D, Fletcher J et al, “Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo.” Stem Cells 26: 894–902. (2008)
79. Chamuleau RA, Deurholt T, Hoekstra R “Which are the right cells to be used in a bioartificial liver?” Metab Brain Dis 20: 327–35. (2005)
80. Payne CM, Samuel K, Pryde A et al, “Persistence of functional hepatocyte-like cells in immune-compromised mice.” Liver Int, 31: 254–62. (2011)
81. Takahashi K, Tanabe K, Ohnuki M et al, “Induction of pluripotent stem cells from adult human fibroblasts by defined factors.” Cell. Nov 30;131(5):861-72. (2007)
82. Yu J, Vodyanik MA, Smuga-Otto K et al, “Induced pluripotent stem cell lines derived from human somatic cells.” Science. Dec 21;318(5858):1917-20. (2007)
83. Sullivan GJ, Hay DC, Park IH et al, “Generation of functional human hepatic endoderm from human induced pluripotent stem cells.” Hepatology, 51: 329–35. (2010)
84. Yasuhito Nagamoto, Kazuo Takayama, Kazuo Ohashi, “Transplantation of a human iPSC-derived hepatocyte sheetincreases survival in mice with acute liver failure.” Journal of Hepatology, vol. 64 1068–1075. (2016)
85. Fausto N, “Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells.” Hepatology, 39: 1477–87. (2004)
86. Dumble ML, Croager EJ, Yeoh GC, Quail EA, “Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma.” Carcinogenesis, 23: 435–45. (2002)
87. Wege H, Le HT, Chui MS, et al, “Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential.” Gastroenterology, 124: 432–44. (2003)
88. Yoon JH, Lee HV, Lee JS, Park JB, Kim CY, “Development of a non-transformed human liver cell line with differentiated- hepatocyte and urea-synthetic functions: applicable for bioartificial liver.” Int J Artif Organs, 22(11): 769–77.(1999)
89. Deurholt T, van Til NP, Chhatta AA et al, “Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes.” BMC Biotechnol, 9: 89. (2009)
90. Chen Y, Li J, Liu X et al, “Transplantation of immortalized human fetal hepatocytes prevents acute liver failure in 90% hepatectomized mice.” Transplant Proc, 42: 1907–14. (2010)
91. Khan AA, Habeeb A, Parveen N et al, “Peritoneal transplantation of human fetal hepatocytes for the treatment of acute fatty liver of pregnancy: a case report.” Trop Gastroenterol, 25: 141–3. (2004)
92. Diekmann S, Bader A, Schmitmeier S, “Present and Future Developments in Hepatic Tissue Engineering for Liver Support Systems: State of the art and future developments of hepatic cell culture techniques for the use in liver support systems.” Cytotechnology, 3: 163–79. (2006)
93. Mahieu-Caputo D, Allain JE, Branger J et al, “Repopulation of athymic mouse liver by cryopreserved early human fetal hepatoblasts.” Hum Gene Ther, 15(12): 1219–28. (2004)
94. Malhi H, Irani AN, Gagandeep S, Gupta S, “Isolation of human progenitor liver epithelial cells with extensive replication capacity and differentiation into mature hepatocytes.” J Cell Sci, 13: 2679–88. (2002)
95. Suzuki A, Zheng Y, Kondo R et al, “Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver.” Hepatology, 32: 1230–9. (200)
96. Suzuki A, Zheng YW, Kaneko S et al, “Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver.” J Cell Biol, 156: 173–84. (2002)
97. Sekiya S, Suzuki A, “Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors.” Nature, 475: 390–3. (2011)
98. Huang P, He Z, Ji S et al, “Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors.” Nature, 475: 386–9. (2011)
99. Aoki K, Mizumoto H, Nakazawa K, Funatsu, K, Kajiwara T, ""Evaluation of a hybrid artificial liver module with liver lobule-like structure in rats with liver failure."" The International Journal of Artificial Organs, 31(1), 55–61, (2008)
100. Mizumoto H, Amimoto N, Miyazawa T, Tani H, Ikeda K, Kajiwara T, ""In vitro and ex vivo Functional Evaluation of a Hollow Fiber-type Bioartificial Liver Module Containing ES Cell- derived Hepatocyte-like Cells."" Advanced Biomedical Engineering. 7, 18-27, (2018).
101. Xiao-Lei Shi, Yimeng Gao, Yupeng Yan et al, “Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes.” Cell Research, 26:206-216. (2016)
102. Warbug O, “On the origin of cancer cells.” Science, 123; 309-314. (1956)
103. Hirschhaeuser F, Menne H, Dittfeld C et al, “Multicellular tumor spheroids: an underestimated tool is catching up again.” J Biotechnol. Jul 1;148(1):3-15. (2010)
104. 劉懐旭; 九州大学修士論文(2016)
105. Xu Z, Liu E, Peng C et al, “Role of hypoxia-inducible-1α in hepatocellular carcinoma cells using a Tet-on inducible system to regulate its expression in vitro.” Oncol Rep; 27(2):573-8. (2012)
106. 永尾雅哉, “酸素による遺伝子発現の調節” タンパク質 核酸 酵素 Vol.41 No.16(1996)
107. Yoshifumi Sato, Tomonori Tsuyama, Chinami Sato et al, “Hypoxia reduces HNF4α/MODY1 protein expression in pancreatic β-cells by activating AMP- activated protein kinase” Journal of biological chemistry, Manuscript M116.767574 (2017)
108. Lukšan O, Dvořáková L, Jirsa M, “HNF-4α regulates expression of human ornithin carbamoyltransferase through interaction with two positive cis-acting regulatory elements located in the proximal promoter.” Folia Biol (Praha), 60(3):133-43. (2014)
109. Tadashi Kashiwagura, David F. Wilson, Maria Erecinska; “Oxygen dependence of cellular metabolism: the effect of O2 tension on gluconeogenesis and urea synthesis in isolated rat hepatocytes” Journal of cellular physiology 120:13-18. (1984)
110. Ulrich C, Krüger B, Köhler H, Riegel W, “Effects of Acidosis on Acute Phase Protein Metabolismin Liver Cells.” Miner Electrolyte Metab 25:228–233 (1999)
111. Fanny Evenou, Teruo Fujii, and Yasuyuki Sakai, “Spontaneous Formation of Highly Functional Three-Dimensional Multilayer from Human Hepatoma Hep G2 Cells Cultured on an Oxygen-Permeable Polydimethylsiloxane Membrane” TISSUE ENGINEERING: Part C Volume 16, Number 2. (2010)
112. Mizumoto H, Amimoto N, Miyazawa T et al, “In vitro and ex vivo Functional Evaluation of a Hollow Fiber-type Bioartificial Liver Module Containing ES Cell- derived Hepatocyte-like Cells.” Adv Biomed Eng 7:18–27. (2018)
113. G.J.Todaro, J.E.DeLarco, H.Marquardt et al, “Control of proliferation in animal cells” Hormones and cell culture, vol 6 113. (1979)
114. Rotem, A., Toner, M., Tompkins, R. G. & MArtin, L. Y, “Oxygen uptake rates in cultured rat hepatocytes”. Biotechnol. Bioeng, 40:1286–1291. (1992)
115. Takahashi Y, Hori Y, Yamamoto T, Urashima T et al, “3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells.” Biosci, May 7;35(3). (2015)
116. Kim K, Ohashi K, Utoh R, Kano K, Okano T et al, “Preserved liver-specific functions of hepatocytes in 3D co-culture with endothelial cell sheets.” Biomaterials. Feb;33(5):1406-13. (2012)
117. Ohkura T, Ohta K, Nagao T, Kusumoto K et al, “Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism.” Drug Metab Pharmacokinet. 29(5):373-8. (2014)
118. Zhong L, Gou J, Deng N et al, “Three-dimensional co-culture of hepatic progenitor cells and mesenchymal stem cells in vitro and in vivo.” Microsc Res Tech. Aug;78(8):688-96. (2015)
119. Okudaira T, Yabuta R, Mizumoto H, Kajiwara T, “Fabrication of a fiber-type hepatic tissue by bottom-up method using multilayer spheroids.” J Biosci Bioeng. 123:739–747. (2017)
120. Xu Z, Liu E, Peng C, Li Y et al, “Role of hypoxia-inducible-1α in hepatocellular carcinoma cells using a Tet-on inducible system to regulate its expression in vitro.” Oncol Rep. Feb;27(2):573-8. (2012)
121. Jun Wu, Aida Platero-Luengo, Masahiro Sakurai et al, “Interspecies Chimerism with Mammalian Pluripotent Stem Cells” Cell. 168, 473–486. (2017)
122. Kimberly A. Homan, David B. Kolesky, Mark A. Skylar-Scott et al, “Bioprinting of 3D Convoluted Renal Proximal Tubules on Perfusable Chips” Scientific Reports volume6, Article number: 34845. (2016)
論文の公開元へ
